Dr. Sarangdhar is a bioinformatics-trained computational scientist with a strong focus towards unraveling latent relationships within biomedical big data. He earned a PhD in Computer Science from the University of Hull, UK in 2011. His research interests include systems pharmacology, developmental pharmacology, cardio-oncology, drug-induced toxicities, and drug repositioning. He has developed a novel platform, AERSMine, to mine the clinical responses of more than 8 million patients to all FDA-approved drugs in order to identify unexpected clinical harm, benefits and alternative treatment choices for individual patients. He is a member of the Children’s Oncology Group and is developing a platform to compare and analyze differential treatment-associated toxicities of specific drugs and drug combinations between pediatric and young adult groups across multiple studies and disease groups.